Journavx (suzetrigine) NDC 85766-243

NDC codes

FDA NDC Directory

Product NDC (as listed)85766-243Labeler and product segments. Claims need a package NDC.

Product NDC at billing width85766-0243Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
85766-243-01	85766024301	100 TABLET, FILM COATED in 1 BOTTLE (85766-243-01)Marketed from Jul 13, 2026
85766-243-20	85766024320	20 TABLET, FILM COATED in 1 BOTTLE (85766-243-20)Marketed from Jul 21, 2026
85766-243-30	85766024330	30 TABLET, FILM COATED in 1 BOTTLE (85766-243-30)Marketed from Jul 13, 2026
85766-243-99	85766024399	10 BLISTER PACK in 1 CARTON (85766-243-99) / 10 TABLET, FILM COATED in 1 BLISTER PACKMarketed from Jul 13, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Journavx
Generic name (nonproprietary): suzetrigine
Active ingredients: Suzetrigine — 50 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Sportpharm LLC
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 219209
Marketing start: Jan 30, 2025
Listing expires: Dec 31, 2027
Other FDA classes: Cytochrome P450 3A Inducers (Mechanism)Sodium Channel Antagonists (Mechanism)
Identifiers: Product ID 85766-243_57223f5a-370d-d9d6-e063-6394a90ab906SPL ID 57223f5a-370d-d9d6-e063-6394a90ab906SPL set ID d229cf71-96ec-4206-960b-d56fafc250acRxCUI 2704833, 2704839UNII LOG73M21H5
Pharmacologic class: Sodium Channel Blocker

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N485766024301 followed by a unit qualifier and the quantity

Package 85766-0243-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 21, 2026.

Indications (excerpt from the label)

JOURNAVX is indicated for the treatment of moderate to severe acute pain, including postoperative pain, in adults. JOURNAVX is a sodium channel blocker indicated for the treatment of moderate to severe acute pain, including postoperative pain, in adults. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 219209

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 219209
Product	Strength	Form · route	Labeler	Product NDC
Journavxsuzetrigine	Suzetrigine 50 mg/1	Tablet, Film coatedOral	Vertex Pharmaceuticals Incorporated	51167-548